+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Narcolepsy - Epidemiology Forecast to 2030

  • ID: 4330792
  • Report
  • January 2021
  • Region: Global
  • 80 pages
  • DelveInsight
This ‘Narcolepsy - Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical, and forecasted Narcolepsy epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered
  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan
Study Period: 2017-2030

Narcolepsy: Understanding

The Narcolepsy epidemiology report gives a thorough understanding of Narcolepsy by including details such as disease classification, etiology, pathophysiology, complications and diagnosis. It also provides treatment algorithms and treatment guidelines for Narcolepsy in the US and Europe. Moreover, the report covers detailed information on the Narcolepsy epidemiology scenario in seven major countries (US, EU5, and Japan).

Epidemiology Perspective:

This section encompassing Narcolepsy epidemiology provides insights about historical and current patient pool and forecasted trends for every seven major countries. The Narcolepsy epidemiology data are studied through all possible divisions to give a better understanding of the Disease scenario in 7MM. This segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports, and views of key opinion leaders.

Detailed Epidemiology Segmentation:

The Narcolepsy epidemiology covered in the report provides historical as well as forecasted Narcolepsy epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report
  • The Narcolepsy report covers a detailed overview explaining its etiology, pathophysiology classification, diagnosis and treatment patterns
  • The Narcolepsy report and model provide an overview of the global trends of Narcolepsy in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
  • The report provides insight into the historical and forecasted patient pool of Narcolepsy in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.
  • The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
  • The report assesses the disease risk and burden and highlights the unmet needs of Narcolepsy.
  • The report provides the segmentation of the Narcolepsy epidemiology
Report Highlights
  • 11-year Forecast of Narcolepsy Epidemiology
  • 7MM Coverage
  • Diagnosed prevalent cases of Narcolepsy
  • Subtype-specific cases of Narcolepsy
  • Clinical manifestations associated with Narcolepsy
  • Age-group wise prevalence of Narcolepsy
KOL Views

The publisher interviews KOLs and include SME’s opinion through primary research to fill the data gaps and validate the secondary research. The opinion helps to understand the total patient population and current treatment pattern. It will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered:
  • What will be the growth opportunities in the 7MM concerning the patient population pertaining to Narcolepsy?
  • What are the key findings pertaining to the Narcolepsy epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Narcolepsy across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden, and unmet needs of Narcolepsy?
  • What are the currently available treatments of Narcolepsy?
Reasons to Buy:

The Narcolepsy Epidemiology report will allow the user to:
  • Develop business strategies by understanding the trends shaping and driving the global Narcolepsy market.
  • Quantify patient populations in the global Narcolepsy market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Narcolepsy therapeutics in each of the markets covered
  • Understand the magnitude of Narcolepsy population by its epidemiology
  • The Narcolepsy Epidemiology Model developed by the publisher is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources
Key Assessments:
  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population
Note: Product cover images may vary from those shown

1 Key Insights

2 Executive Summary of Narcolepsy

3 SWOT Analysis for Narcolepsy

4 Narcolepsy Epidemiology Overview at a Glance
4.1 Patient Share (%) Distribution of Narcolepsy in 2017
4.2 Patient Share (%) Distribution of Narcolepsy in 2030

5 Narcolepsy Market Overview at a Glance
5.1 Market Share (%) Distribution of Narcolepsy in 2017
5.2 Market Share (%) Distribution of Narcolepsy in 2030

6 Disease Background and Overview: Narcolepsy
6.1 Introduction
6.2 Signs and Symptoms
6.3 Complications
6.4 Pathophysiology
6.5 Etiology
6.6 Risk Factors
6.7 Diagnosis

7 Epidemiology and Patient Population
7.1 Key Findings
7.2 Population and Forecast Parameters

8 7MM Total Prevalent Patient Population of Narcolepsy
8.1 The United States
8.1.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United States
8.1.2 Subtype-specific cases of Narcolepsy in the United States
8.1.3 Clinical Manifestations associated with Narcolepsy
8.1.4 Age-group wise Prevalence of Narcolepsy
8.2 Germany
8.2.1 Diagnosed Prevalent Patient Population of Narcolepsy in Germany
8.2.2 Subtype-specific cases of Narcolepsy in Germany
8.2.3 Clinical Manifestations associated with Narcolepsy
8.2.4 Age-group wise Prevalence of Narcolepsy
8.3 France
8.3.1 Diagnosed Prevalent Patient Population of Narcolepsy in France
8.3.2 Subtype-specific cases of Narcolepsy in France
8.3.3 Clinical Manifestations associated with Narcolepsy
8.3.4 Age-group wise Prevalence of Narcolepsy
8.4 Italy
8.4.1 Diagnosed Prevalent Patient Population of Narcolepsy in Italy
8.4.2 Subtype-specific cases of Narcolepsy in Italy
8.4.3 Clinical Manifestations associated with Narcolepsy
8.4.4 Age-group wise Prevalence of Narcolepsy
8.5 Spain
8.5.1 Diagnosed Prevalent Patient Population of Narcolepsy in Spain
8.5.2 Subtype-specific cases of Narcolepsy in Spain
8.5.3 Clinical Manifestations associated with Narcolepsy
8.5.4 Age-group wise Prevalence of Narcolepsy
8.6 United Kingdom
8.6.1 Diagnosed Prevalent Patient Population of Narcolepsy in the United Kingdom
8.6.2 Subtype-specific cases of Narcolepsy in the United Kingdom
8.6.3 Clinical Manifestations associated with Narcolepsy
8.6.4 Age-group wise Prevalence of Narcolepsy
8.7 Japan
8.7.1 Diagnosed Prevalent Patient Population of Narcolepsy in Japan
8.7.2 Subtype-specific cases of Narcolepsy in Japan
8.7.3 Clinical Manifestations associated with Narcolepsy
8.7.4 Age-group wise Prevalence of Narcolepsy

9 Treatment and Management
9.1 Guideline and Management
9.1.1 American Academy of Sleep Medicine Guidelines
9.1.2 European Federation of Neurological Societies (EFNS) Guidelines

10 Unmet Needs

11 Appendix
11.1 Report Methodology

12 Publisher Capabilities

13 Disclaimer

14 About the Publisher

List of Tables
Table 1: Summary of Narcolepsy, Epidemiology, and Key Events (2017-2030)
Table 2:Total Prevalent Patient Population of Narcolepsy in the 7MM (2017-2030)
Table 3: Prevalent Cases of Narcolepsy in the United States (2017-2030)
Table 4: Subtype-specific cases of Narcolepsy in the United States (2017-2030)
Table 5: Clinical Manifestations associated with Narcolepsy in the United States (2017-2030)
Table 6: Age-group wise Prevalence of Narcolepsy (2017-2030)
Table 7: Prevalent Cases of Narcolepsy in Germany (2017-2030)
Table 8: Subtype-specific cases of Narcolepsy in Germany (2017-2030)
Table 9:Clinical Manifestations associated with Narcolepsy in Germany (2017-2030)
Table 10: Age-group wise Prevalence of Narcolepsy (2017-2030)
Table 11: Prevalent Cases of Narcolepsy in France (2017-2030)
Table 12: Subtype-specific cases of Narcolepsy in France (2017-2030)
Table 13: Clinical Manifestations associated with Narcolepsy in France (2017-2030)
Table 14: Age-group wise Prevalence of Narcolepsy (2017-2030)
Table 15: Prevalent Cases of Narcolepsy in Italy (2017-2030)
Table 16:Subtype-specific cases of Narcolepsy in Italy (2017-2030)
Table 17: Clinical Manifestations associated with Narcolepsy in Italy (2017-2030)
Table 18: Age-group wise Prevalence of Narcolepsy (2017-2030)
Table 19: Prevalent Cases of Narcolepsy in Spain (2017-2030)
Table 20: Subtype-specific cases of Narcolepsy in Spain (2017-2030)
Table 21: Clinical Manifestations associated with Narcolepsy in Spain (2017-2030)
Table 22: Age-group wise Prevalence of Narcolepsy (2017-2030)
Table 23: Prevalent Cases of Narcolepsy in the United Kingdom (2017-2030)
Table 24:Subtype-specific cases of Narcolepsy in the United Kingdom (2017-2030)
Table 25: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017-2030)
Table 26: Age-group wise Prevalence of Narcolepsy (2017-2030)
Table 27: Prevalent Cases of Narcolepsy in Japan (2017-2030)
Table 28: Subtype-specific cases of Narcolepsy in Japan (2017-2030)
Table 29: Clinical Manifestations associated with Narcolepsy in Japan (2017-2030)
Table 30: Age-group wise Prevalence of Narcolepsy in Japan (2017-2030)

List of Figures
Figure 1: SWOT Analysis
Figure 2: Complications of Narcolepsy
Figure 3: Pathophysiology of Narcolepsy
Figure 4: Prevalent Cases of Narcolepsy in the 7MM (2017-2030)
Figure 5: Diagnosed Prevalent Cases of Narcolepsy in the United States (2017-2030)
Figure 6: Subtype-specific cases of Narcolepsy in the United States (2017-2030)
Figure 7: Clinical Manifestations associated with Narcolepsy in the United States (2017-2030)
Figure 8: Age-group wise Prevalence of Narcolepsy (2017-2030)
Figure 9: Diagnosed Prevalent Cases of Narcolepsy in Germany (2017-2030)
Figure 10: Subtype-specific cases of Narcolepsy in Germany (2017-2030)
Figure 11: Clinical Manifestations associated with Narcolepsy in Germany (2017-2030)
Figure 12: Age-group wise Prevalence of Narcolepsy (2017-2030)
Figure 13: Diagnosed Prevalent Cases of Narcolepsy in France (2017-2030)
Figure 14: Subtype-specific cases of Narcolepsy in France (2017-2030)
Figure 15: Clinical Manifestations associated with Narcolepsy in France (2017-2030)
Figure 16: Age-group wise Prevalence of Narcolepsy (2017-2030)
Figure 17: Diagnosed Prevalent Cases of Narcolepsy in Italy (2017-2030)
Figure 18: Subtype-specific cases of Narcolepsy in Italy (2017-2030)
Figure 19: Clinical Manifestations associated with Narcolepsy in Italy (2017-2030)
Figure 20: Age-group wise Prevalence of Narcolepsy (2017-2030)
Figure 21: Diagnosed Prevalent Cases of Narcolepsy in Spain (2017-2030)
Figure 22: Subtype-specific cases of Narcolepsy in Spain (2017-2030)
Figure 23: Clinical Manifestations associated with Narcolepsy in Spain (2017-2030)
Figure 24: Age-group wise Prevalence of Narcolepsy (2017-2030)
Figure 25: Diagnosed Prevalent Cases of Narcolepsy in the United Kingdom (2017-2030)
Figure 26: Subtype-specific cases of Narcolepsy in the United Kingdom (2017-2030)
Figure 27: Clinical Manifestations associated with Narcolepsy in the United Kingdom (2017-2030)
Figure 28: Age-group wise Prevalence of Narcolepsy (2017-2030)
Figure 29: Diagnosed Prevalent Cases of Narcolepsy in Japan (2017-2030)
Figure 30: Subtype-specific cases of Narcolepsy in Japan (2017-2030)
Figure 31: Clinical Manifestations associated with Narcolepsy in Japan (2017-2030)
Figure 32: Age-group wise Prevalence of Narcolepsy (2017-2030)
Figure 33: Decision tree for starting and then adapting the therapy for excessive daytime sleepiness and cataplexy
Figure 34: Therapies for the treatment of excessive daytime sleepiness and irresistible episodes of sleep with Narcolepsy
Figure 35: Non-pharmacological treatment practices for Narcolepsy
Figure 36: Unmet Needs for Narcolepsy

Note: Product cover images may vary from those shown
Adroll
adroll